NTLA
Intellia Therapeutics, Inc.
There isn't enough reported data to score NTLA yet.
NTLA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NTLA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NTLA PE Valuation
NTLA has no meaningful PE right now: it lost money over the past year.
NTLA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NTLA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NTLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.33 | +$0.94 |
| Q2 2026 | -$3.34 | +$1.35 |
| Q1 2026 | -$3.52 | +$1.71 |
| Q4 2025 | -$3.81 | +$1.44 |
| Q3 2025 | -$4.27 | +$1.17 |
| Q2 2025 | -$4.69 | +$0.79 |
| Q1 2025 | -$5.23 | +$0.13 |
| Q4 2024 | -$5.25 | +$0.16 |
NTLA is still losing money, but less than at its worst: $3.33 per share over the past year, against $6.16 at its worst in late 2022.
NTLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.2M | -48% |
| Q2 2026 | $7.7M | -46% |
| Q1 2026 | $15M | -9.5% |
| Q4 2025 | $23M | +79% |
| Q3 2025 | $13.8M | +51% |
| Q2 2025 | $14.2M | +105% |
| Q1 2025 | $16.6M | -43% |
| Q3 2024 | $9.1M | -24% |
NTLA's revenue has slid since its 2024 peak: $7M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1708% | -899 points |
| Q2 2026 | -1472% | -700 points |
| Q1 2026 | -668% | +59 points |
| Q4 2025 | -429% | +631 points |
| Q3 2025 | -809% | +780 points |
| Q2 2025 | -772% | +1226 points |
| Q1 2025 | -727% | -333 points |
| Q4 2024 | -1060% | N/A |
NTLA's operating margin was −1708% last quarter, down 899 points from the same quarter a year ago, near the bottom of its range since 2019.
NTLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$86.3M | -$9.4M |
| Q2 2026 | -$84.9M | +$14.9M |
| Q1 2026 | -$117.4M | +$32.2M |
| Q4 2025 | -$69.4M | +$16.8M |
| Q3 2025 | -$76.9M | +$9.2M |
| Q2 2025 | -$99.9M | -$40.7M |
| Q1 2025 | -$149.7M | -$26.5M |
| Q4 2024 | -$86.2M | +$8.4M |
NTLA has burned cash in almost every quarter: −$358M over the past year, against −$413M the year before.
NTLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5% | +6.7M shares |
| 1 year | +27% | +30M shares |
| 3 years | +58% | +51.5M shares |
| 5 years | +106% | +72M shares |
| Available history | +184% | +90.8M shares |
NTLA has 140M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
NTLA Net Leverage
NTLA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NTLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 30.2 | Neutral |
NTLA's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
NTLA PE vs Healthcare Sector
NTLA has no meaningful PE right now: it lost money over the past year.
NTLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 10% below |
| 20 week MA | $12.2 | 14% below |
| 50 week MA | $12.5 | 16% below |
| 100 week MA | $11.9 | 11% below |
| 200 week MA | $20.8 | 49% below |
NTLA is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
NTLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.4 | $62.1 | +304% |
| 2021 | $62.1 | $126.8 | +104% |
| 2022 | $126.8 | $35.0 | -72% |
| 2023 | $35.0 | $30.5 | -13% |
| 2024 | $30.5 | $12.0 | -61% |
| 2025 | $12.0 | $9.44 | -21% |
| 2026 YTD | $9.44 | $10.6 | +12% |
NTLA has finished four years in a row lower, and it's up 12% so far in 2026.